Company Overview
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Why Investors Should Care
Revenue has grown at a 1644.5% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.06.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $45.95M (+4174.5% YoY); net profit $-48.88M.
- 5-Year Trend Long-term compounding — revenue CAGR 1644.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 1,644.45% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +214.37% |
| 6 Months: | +27.69% |
| 3 Months: | +17.98% |
| 1 Month: | -7.03% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)41.00 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 1644.5% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SEPN Septerna, Inc. R2KR3KPHARMA | 36.75 | -47.12 | $1.66B | 0.00% | -13.41% | -9.26% | 1,644.45% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 33.00K | 317.00K | 370.00K | 176.00K | 219.00K | 119.00K | 21.50M | 26.52M |
| Operating Income | - | - | -12.04M | -15.49M | -18.07M | -22.55M | -25.91M | -28.98M | 2.61M | -13.30M |
| Net Income | -9.17M | -10.60M | -10.95M | -14.10M | -16.51M | -20.52M | -21.48M | -24.84M | 8.17M | -8.64M |
| Diluted EPS | - | - | -5.45 | -6.35 | -7.03 | -8.40 | -0.49 | -0.56 | 0.18 | -0.19 |
| R&D Expense | - | - | 9.28M | 13.15M | 15.04M | 17.83M | 19.27M | 22.19M | 24.26M | 29.54M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 151.00K | 1.07M | 45.95M |
| Operating Income | 2.08M | -80.82M | -68.30M |
| Net Income | 4.18M | -71.80M | -48.88M |
| Diluted EPS | 0.29 | -7.26 | -1.10 |
| R&D Expense | 35.98M | 65.34M | 97.58M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | 130.87M | 456.55M | 596.19M |
| Total Equity | -44.20M | -38.37M | 420.05M | 381.93M |
| Cash & Equivalents | - | 88.48M | 238.20M | 120.72M |
| Total Liabilities | - | 20.03M | 36.51M | 214.26M |
| Current Liabilities | - | 6.91M | 12.85M | 86.93M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -38.72M | -67.47M | 110.19M |
| Investing Cash Flow | 22.12M | -160.60M | -229.35M |
| Financing Cash Flow | 74.52M | 377.78M | 1.69M |
| Capital Expenditure | -2.88M | -2.10M | -518.00K |
| Free Cash Flow | -41.60M | -69.57M | 109.67M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | 1,374.2% | -7,518.4% | -148.6% |
| Net Margin % | 2,768.2% | -6,678.9% | -106.4% |
| ROE % | -10.9% | -17.1% | -12.8% |
| ROCE % | 1.7% | -18.2% | -13.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 14.99% | 7.00M | $272.21M |
| 2 | Trv Gp V, LLC | 13.32% | 6.22M | $241.85M |
| 3 | Driehaus Capital Management, LLC | 9.50% | 4.43M | $172.49M |
| 4 | Trv Gp VI, LLC | 9.02% | 4.21M | $163.88M |
| 5 | Samsara BioCapital, LLC | 6.75% | 3.15M | $122.53M |
| 6 | Goldman Sachs Group Inc | 6.56% | 3.06M | $119.17M |
| 7 | Blackrock Inc. | 4.14% | 1.93M | $75.18M |
| 8 | Siren, L.L.C. | 4.07% | 1.90M | $73.93M |
| 9 | Avoro Capital Advisors LLC | 2.87% | 1.34M | $52.04M |
| 10 | Jupiter Topco LLC | 2.80% | 1.31M | $50.87M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SEPN
New Septerna (SEPN) chief medical officer reports zero share holdings - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQTUhFR2hWYW4tWmQ3aFJJRXlMTmhiS3V0em1KWXlXV3RVZ1pBNW85X1EtVjAxZ1Z0WFlzUXFxa29oaVEyWWVXQ3RTV05CY1JUTGUyaXBTR3VOVE9iTlVHZnZqbEJrLWJFYXJsa2VTa3FoNk1HRWFVRnhXUEVKWTA1NjhIcnZLYkJoNGVXbV…
Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQNVY0SURhWVNNdkdGZktsNU1mMkR1Y25BbE5ncHhEVUVVNE9nUk9ndXN4RDU0ZmlNYlVTNVBteENaUGxETlg1OE80WFdSY3JDcExlLXNUTDlGcHhicHJ3M0tJdGRSYWNpdEdnTW16WXJJekstaUdOdHFWLXFiUnNGYVhCOFNtZ1RWaVNYT3…
Insider Sale: 10% owner at $SEPN Sells 141 Shares - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxQYlFQNS1QY05rdmNrVG82U29qZC10bUpOS3pLZ19nZ0NMWEVvMXd4UnpYSU1DNVlsckoxS0lFT0hXc2Z1VHg5R0ZUSlg1ZlpoWWQ5b2FHWFRKTTNNLVRWU0tXTTAxT0sxWlR0VU5XeFNuVEZ3VXZWN3YzN2Ryc1N6WG9Yc1JIa1dWbEdsTT…
Septerna (SEPN) Names A New CMO, Is The Upside Already Priced In? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxQdEZKYk9CSVBBazFLRVpoeFY2aTdQMEdKbjJ3aXhTMVRTNVVvNE1Bc0V3TENXR1hLT3ZMdzRROHFETFpaUVBSZ3AzQndDNEktRkI1NFlXdHhwdWJMc0MyaXFCbkUtaFZoOWF6dS1uQ2otdGR0ZkVZUmJFMTU5X0JvTDh3S2VPR19iWk44X0…
Septerna SVP Daniel Long sells $126,077 in company stock By Investing.com - Investing.com Nigeria
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxPSWl6d3AzWktvVVQtNEhaX1ctR1JDazFJMk0tVE1IczBwY0FBT2RfUGI0VWlkV2RVejhrcE9HNXctUVNWUGtWM3Z1OWNERzF1OEtQNUhxeGFXaU45MndHM1JqR0hzay1LdXh3bHNaUGJrQWEwMGRKRXdqaVllNXY1bkRSeDBFSjFJUllLU0…
SEPN - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE4zcmNQOGk0c0xIWGR6QzliT21Cb3otRy1TQWp6WEdYV2dIZXoyLU40WGY4cXduNTlBSEY3R1BDZTRKRDJQd1E?oc=5" target="_blank">SEPN</a> <font color="#6f6f6f">Finviz</font>…
SEPN — Frequently Asked Questions
What is the current share price of Septerna, Inc. (SEPN)?
As of 2026-09-07 16:24 PDT, Septerna, Inc. (SEPN) trades at $36.75 on NasdaqGM. Its 52-week range is $10.93 to $48.19.
What is the market capitalisation of SEPN?
Septerna, Inc. (SEPN) has a market capitalisation of $1.66B on NasdaqGM.
What is the P/E ratio of SEPN?
SEPN trades at a trailing price-to-earnings (P/E) ratio of -47.12. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 4.61.
What is the return on equity (ROE) of SEPN?
SEPN has a return on equity (ROE) of -9.26%. Its return on capital employed (ROCE) is -13.41%.
Is SEPN a good stock to buy?
This page provides a data-driven analysis of Septerna, Inc. (SEPN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.